Akebia Therapeutics, Inc. (AKBA Quick QuoteAKBA - Free Report) was a big mover last session, as its shares rose over 19% on the day. The move came after the company signed a deal with Japanese drugmaker Otsuka Pharmaceutical to develop and sell vadadustat, Akebia's oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor to treat anemia associated with chronic kidney disease. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $7.87 to $9.09 in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Akebia Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

AKEBIA THERAP Price

 

AKEBIA THERAP Price | AKEBIA THERAP Quote

A better-ranked stock in the medical-drugs space is Indivior PLC , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is AKBA going up? Or down? Predict to see what others think: Up or Down

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>